Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription 09.06.2025 2 Am J Clin Pathol 11 Ann Surg Oncol 7 BMC Cancer 2 Breast Cancer 1 Breast Cancer (Dove Med Press) 6 Breast Cancer Res 11 Breast Cancer Res Treat 2 Cancer 3 Cancer Epidemiol Biomarkers Prev 4 Clin Breast Cancer 2 Eur J Cancer 2 Eur J Surg Oncol 1 Exp Cell Res 1 Histopathology 4 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Biol Chem 2 J Clin Invest 2 J Nucl Med 5 J Surg Oncol 6 N Engl J Med 1 NPJ Breast Cancer 1 Oncology 8 PLoS One 3 Radiol Imaging Cancer 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Pathol

1. WILCOCK D, Sirohi D, Coleman JF, Adelhardt P, et al
   HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry.
   Am J Clin Pathol. 2025;163:837-846.
   PubMed         Abstract available
   
   
2. HUNTER N, Han L, Corbin H, Konnick EQ, et al
   Clinicopathologic and molecular characterization of low-grade, early-stage, and HER2-positive invasive breast carcinoma.
   Am J Clin Pathol. 2025;163:854-865.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. TAYLOR CD, Wang T, Sinco BR, Pilewskie M, et al
   National Variation in Implementation of Sentinel Lymph Node Biopsy for Clinically Node-Positive Patients Undergoing Neoadjuvant Therapy.
   Ann Surg Oncol. 2025;32:4874-4882.
   PubMed         Abstract available
   
   
4. THILL M, Ghilli M, Roncella M, Kelling K, et al
   A Multi-institutional Study to Evaluate the Effectiveness and Safety of a Supine MRI-Based Guidance System, the Breast Cancer Locator(TM), for Breast Conserving Surgery in Patients with Nonpalpable Breast Cancer.
   Ann Surg Oncol. 2025 Jun 6. doi: 10.1245/s10434-025-17513.
   PubMed         Abstract available
   
   
5. NIERENBERG TC, Crowell KA, Wang T, Rosenberger LH, et al
   Adjuvant Radiation vs Endocrine Therapy After Lumpectomy for Early-Stage Breast Cancer in Older Women: Analysis of Real-World Survival Outcomes.
   Ann Surg Oncol. 2025 Jun 6. doi: 10.1245/s10434-025-17532.
   PubMed         Abstract available
   
   
6. FLANAGAN MR, van den Bruele AMB, Downs-Canner SM, Thomas SM, et al
   ASO Visual Abstract: A Multi-institutional Analysis of Contralateral Axillary Metastases-Advanced Local-Regional Disease Divergent from Stage IV Breast Cancer.
   Ann Surg Oncol. 2025 Jun 3. doi: 10.1245/s10434-025-17563.
   PubMed        
   
   
7. HOSANG KM, Bleicher RJ, Yao KA, Dietz JR, et al
   Low Socioeconomic Status at the Patient and Institutional Level Impact Achievement of Breast Cancer Quality Standards.
   Ann Surg Oncol. 2025 Jun 2. doi: 10.1245/s10434-025-17529.
   PubMed         Abstract available
   
   
8. VAN DEN BRUELE AB, Rosenberger LH, Downs-Canner S, Flanagan MR, et al
   ASO Author Reflections: Contralateral Axillary Lymph Node Metastasis of Breast Cancer: Time to Re-evaluate Conventional Thinking.
   Ann Surg Oncol. 2025 Jun 2. doi: 10.1245/s10434-025-17535.
   PubMed        
   
   
9. SAH R, Mathur A, Veldi VDK
   Letter to the Editor Regarding "Differential Effects of Endocrine Therapy Type on Quality of Life in Older (>/= 70 Years) Women with Early-Stage Breast Cancer".
   Ann Surg Oncol. 2025 May 31. doi: 10.1245/s10434-025-17593.
   PubMed        
   
   
10. SILVERSTEIN MJ, Kim B, Lin K, Lloyd S, et al
    Intraoperative Radiation Therapy (IORT) for Breast Cancer: The Final Analysis of a Prospective Cohort of 1828 Cases.
    Ann Surg Oncol. 2025 May 31. doi: 10.1245/s10434-025-17546.
    PubMed         Abstract available
    
    
11. ORSI C, Davis T, Swindall R, Wadle C, et al
    ASO Visual Abstract: Disparities in Timeliness of Breast Cancer Treatment in a Rural Setting; Rural Breast Cancer Treatment Disparities.
    Ann Surg Oncol. 2025 May 30. doi: 10.1245/s10434-025-17476.
    PubMed        
    
    
12. CHIARELLA LS, Huelsboemer L, Diatta F, Klimitz FJ, et al
    The Five-Item Modified Frailty Index Predicts Adverse Surgical Outcomes in Patients Undergoing Mastectomy.
    Ann Surg Oncol. 2025;32:4829-4837.
    PubMed         Abstract available
    
    
13. SWITALLA KM, Falade IO, Quirarte A, Baxter M, et al
    Positive Margin Rates After Breast-Conserving Surgery by Histologic Subtype: A Systematic Review and Meta-analysis Evaluating the Impact of Oncoplastic Surgery.
    Ann Surg Oncol. 2025;32:4899-4909.
    PubMed         Abstract available
    
    

    
    BMC Cancer

14. AL-MATRAFI AR, Bedair KF, Srinivasan S, Palmer C, et al
    Clinical and pharmacogenomic predictors of survival in tamoxifen treated breast cancer female patients: a real-world study.
    BMC Cancer. 2025;25:974.
    PubMed         Abstract available
    
    
15. BREEK K, Abuhalima D, Salameh H, Al-Jabi SW, et al
    Self-reported side effects of breast cancer treatment and its impact on quality of life: a multicenter cross-sectional study in a low- and middle-income country.
    BMC Cancer. 2025;25:975.
    PubMed         Abstract available
    
    
16. LIANG Y, Xu H, Lin J, Tang W, et al
    Multi-modal radiomics model based on four imaging modalities for predicting pathological complete response to neoadjuvant treatment in breast cancer.
    BMC Cancer. 2025;25:985.
    PubMed         Abstract available
    
    
17. EBRAHIM NAA, Hussein MA, Sobeih ME, Amin NH, et al
    From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer- insights from the national cancer institute.
    BMC Cancer. 2025;25:1008.
    PubMed         Abstract available
    
    
18. EL-JAMMAL M, Saifi O, Bazan J, Zeidan YH, et al
    Radiation therapy in clinically node positive HER2 positive breast cancer after primary systemic therapy and breast conserving surgery: pooled analysis of TRYPHAENA and NeoSphere trials.
    BMC Cancer. 2025;25:996.
    PubMed         Abstract available
    
    
19. KARIMI MA, Khadem R, Haraj A, Farahani MA, et al
    The impact of sodium-glucose cotransporter-2 inhibitors on breast cancer and cancer-related mortality: a systematic review and meta-analysis of randomized controlled trials.
    BMC Cancer. 2025;25:991.
    PubMed         Abstract available
    
    
20. OSBORNE A, Adnani QES, Ahinkorah BO
    Breast cancer incidence in Indonesia: a sex-disaggregated analysis using WHO health equity assessment toolkit data.
    BMC Cancer. 2025;25:986.
    PubMed         Abstract available
    
    

    
    Breast Cancer

21. XU G, Zhao K, Zhou X, Zhang L, et al
    Clinical application of 90-gene expression test in a patient with occult breast cancer: a case report and literature review.
    Breast Cancer. 2025 Jun 5. doi: 10.1007/s12282-025-01728.
    PubMed         Abstract available
    
    
22. PENG G, Lee G, Kim S, Chen QY, et al
    Meta-analysis of smoking and breast cancer risk: by age of smoking initiation.
    Breast Cancer. 2025 Jun 3. doi: 10.1007/s12282-025-01715.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

23. LV H, Zhang B, Weng X, Li Y, et al
    CD151 Promotes Cancer Progression in Triple-Negative Breast Cancer by Inducing EMT through the MAPK Signaling Pathway.
    Breast Cancer (Dove Med Press). 2025;17:455-470.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

24. LIU PH, Tsai CF, Hsu YC, Wu CY, et al
    Aromatase inhibitors therapy and major osteoporotic fracture risk in postmenopausal breast cancer patients: a nationwide real-world cohort study.
    Breast Cancer Res. 2025;27:95.
    PubMed         Abstract available
    
    
25. ZHONG HJ, Zhen Y, Chen S, Shi W, et al
    Advances in CTC and ctDNA detection techniques: opportunities for improving breast cancer care.
    Breast Cancer Res. 2025;27:97.
    PubMed         Abstract available
    
    
26. HU C, Zhang S, Duan F, Huang X, et al
    Sialylated IgG expressed in triple-negative breast cancer cells promotes cancer progression by promoting glycolysis.
    Breast Cancer Res. 2025;27:96.
    PubMed         Abstract available
    
    
27. NOKIN MJ, Bellier J, Durieux F, Peulen O, et al
    Correction: Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
    Breast Cancer Res. 2025;27:99.
    PubMed        
    
    
28. CHEN C, Yao H, Jie H, Liang Z, et al
    SENP5 drives breast cancer progression through deSUMOYlation of CDK1.
    Breast Cancer Res. 2025;27:100.
    PubMed         Abstract available
    
    
29. DING P, Pei S, Zhai Y, Qu Z, et al
    Dissecting the tumor microenvironment in primary breast angiosarcoma: insights from single-cell RNA sequencing.
    Breast Cancer Res. 2025;27:101.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

30. ULENE SR, Wang S, Cook JR, McAuley F, et al
    Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer.
    Breast Cancer Res Treat. 2025 Jun 4. doi: 10.1007/s10549-025-07745.
    PubMed         Abstract available
    
    
31. LEE KT, Hu B, Martinez Tyson D, Geiss C, et al
    A mixed-methods study characterizing experiences of medical oncologists' use of gonadotropin-releasing hormone agonists for treatment of breast cancer.
    Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07734.
    PubMed         Abstract available
    
    
32. COHEN LN, Rogers CC, Lloren JIC, Kamaraju S, et al
    National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016-2021: The impact of the KATHERINE trial.
    Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07750.
    PubMed         Abstract available
    
    
33. WING SE, Liu Y, Zheng F, Hamm NC, et al
    Insurer and patient costs for repeat breast surgery after initial lumpectomy for breast cancer.
    Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07735.
    PubMed         Abstract available
    
    
34. WEHBE A, Katlin F, Sharma E, Hans M, et al
    Breast imaging recommendations for young females (age < 40 years) with >/= 20% lifetime breast cancer risk: practice patterns at a specialized clinic.
    Breast Cancer Res Treat. 2025 Jun 1. doi: 10.1007/s10549-025-07738.
    PubMed         Abstract available
    
    
35. MUSTAFA NM, Mustafa MT, Abushanab AK, Alakhras HM, et al
    Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2025 May 31. doi: 10.1007/s10549-025-07737.
    PubMed         Abstract available
    
    
36. BADER G, Quintanilha JCF, Veney D, Graf RP, et al
    Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study.
    Breast Cancer Res Treat. 2025 May 30. doi: 10.1007/s10549-025-07740.
    PubMed         Abstract available
    
    
37. JASPER JM, Vora H, Kantor O, McGrath M, et al
    Management of ipsilateral breast tumor recurrence after prior breast conservation therapy.
    Breast Cancer Res Treat. 2025;212:361-369.
    PubMed         Abstract available
    
    
38. AKTAS A, Gurleyik MG, Akkus D, Ucur Z, et al
    Invasive lobular breast carcinoma variants; clinicopathological features and patient outcomes.
    Breast Cancer Res Treat. 2025;212:347-359.
    PubMed         Abstract available
    
    
39. YAO J, Zhou W, Jia X, Zhu Y, et al
    Machine learning prediction of pathological complete response to neoadjuvant chemotherapy with peritumoral breast tumor ultrasound radiomics: compare with intratumoral radiomics and clinicopathologic predictors.
    Breast Cancer Res Treat. 2025;212:325-336.
    PubMed         Abstract available
    
    
40. YI ZL, Yang BB, Zhang JN, Zhao MJ, et al
    Radiation recall dermatitis induced by abemaciclib with successful rechallenge: a case series and literature review.
    Breast Cancer Res Treat. 2025;212:189-193.
    PubMed         Abstract available
    
    

    
    Cancer

41. AUBUCHON KE, Galvan CJC, Duron Y, Sampayo I, et al
    Randomized trial of a community-based, culturally tailored intervention: High engagement among Latina breast cancer survivors.
    Cancer. 2025;131:e35842.
    PubMed         Abstract available
    
    
42. FUMAGALLI IA, Warner ET, Llanos AAM, Quesenberry CP, et al
    Racial and ethnic variation in body composition and prognosis of nonmetastatic breast cancer.
    Cancer. 2025;131:e35926.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

43. MCTIERNAN A
    Lifestyle and Breast Cancer Risk: How Does It All Add Up?
    Cancer Epidemiol Biomarkers Prev. 2025;34:833-835.
    PubMed         Abstract available
    
    
44. FENLON J, Van Bibber N, Mahlow J, Yamoah K, et al
    Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers.
    Cancer Epidemiol Biomarkers Prev. 2025;34:860-867.
    PubMed         Abstract available
    
    
45. KELLY RL, Liu Y, Harris AR, Peng C, et al
    The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages.
    Cancer Epidemiol Biomarkers Prev. 2025;34:868-874.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

46. NEPUTE JA, Peratikos M, Toledano AY, Salvas JP, et al
    Improved Breast Cancer Detection with Artificial Intelligence in a Real-World Digital Breast Tomosynthesis Screening Program.
    Clin Breast Cancer. 2025 May 9:S1526-8209(25)00120.
    PubMed         Abstract available
    
    
47. ZHANG JN, Zhou XR, Yi ZL, Tian XY, et al
    The Construction of a New Prognostic Model of Breast Cancer and the Exploration of Drug Sensitivity Based on Machine Learning for Glycosylation-Related Genes.
    Clin Breast Cancer. 2025 May 10:S1526-8209(25)00117.
    PubMed         Abstract available
    
    
48. O'SHAUGHNESSY J, Sousa S, Cruz J, Fallowfield DL, et al
    Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study.
    Clin Breast Cancer. 2025 May 3:S1526-8209(25)00107.
    PubMed         Abstract available
    
    
49. CHEN L, Su Y, Wang Y, Yu Y, et al
    Ultrasound Radiomics-Based Machine Learning and SHapley Additive exPlanations Method Predicting Pathological Prognostic Stage in Breast Cancer: A Bicentric and Validation Study.
    Clin Breast Cancer. 2025 May 8:S1526-8209(25)00114.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

50. DI MICCO R, Botteri E, Canevari C, Gallivanone F, et al
    [(18)F]FDG PET/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial.
    Eur J Cancer. 2025;224:115519.
    PubMed         Abstract available
    
    
51. RUGGIERO E, Sharma S, Di Castelnuovo A, Costanzo S, et al
    Olive oil consumption and risk of breast cancer: Prospective results from the Moli-sani Study, and a systematic review of observational studies and randomized clinical trials.
    Eur J Cancer. 2025;224:115520.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

52. AHMED IA, Bano S
    Additional breast lesions on MRI in patients with small early-stage luminal-type breast cancer: Implications for future thermal ablation treatment.
    Eur J Surg Oncol. 2025;51:110173.
    PubMed        
    
    
53. LI Z, Wang F, Kou X, Couban RJ, et al
    Intercostobrachial nerve preservation during breast cancer surgery to prevent chronic postsurgical pain: A systematic review and meta-analysis of randomized controlled trials.
    Eur J Surg Oncol. 2025;51:110214.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

54. KUMAI J, Sasagawa S, Yui Y
    Metastatic breast cancer cells adapt to a soft environment with limited involvement of mechanotransduction.
    Exp Cell Res. 2025;450:114629.
    PubMed         Abstract available
    
    

    
    Histopathology

55. LEE AHS, Rakha EA, Hodi Z, Abbas A, et al
    Retesting of oestrogen receptor, progesterone receptor and HER2 status of invasive carcinoma of the breast after neoadjuvant chemotherapy.
    Histopathology. 2025;87:58-67.
    PubMed         Abstract available
    
    

    
    Int J Cancer

56. CHEN Y, Salas LA, Marotti JD, Jenkins NP, et al
    Reply to: "Comments on the paper 'Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer' by Y. Chen et al.".
    Int J Cancer. 2025;157:590-591.
    PubMed        
    
    
57. BHIMANI J, Wang P, Gallagher GB, O'Connell K, et al
    Patient factors and modifications to intended chemotherapy for women with Stages I-IIIA breast cancer.
    Int J Cancer. 2025 Jun 2. doi: 10.1002/ijc.35494.
    PubMed         Abstract available
    
    
58. NIEDERMAYER K, Schaffler H, Vlachos G, Greco S, et al
    Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients.
    Int J Cancer. 2025 Jun 2. doi: 10.1002/ijc.35498.
    PubMed         Abstract available
    
    
59. LONNING PE, Nikolaienko O, Knappskog S
    Comments on the paper "Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer" by Y. Chen et al.
    Int J Cancer. 2025;157:588-589.
    PubMed        
    
    

    
    Int J Radiat Oncol Biol Phys

60. GERBER NK, Sheng JY, Thompson A, Wright J, et al
    Multimodality Treatment De-Intensification in Node-Negative, Hormone-Receptor Breast Cancer: What Are the Limits?
    Int J Radiat Oncol Biol Phys. 2025 Jun 1:S0360-3016(25)00551.
    PubMed         Abstract available
    
    

    
    J Biol Chem

61. ZHANG X, Zhuang M, Zhang H, Zhu Y, et al
    Melatonin-mediated cGAS-STING signal in senescent macrophages promote TNBC chemotherapy resistance and drive the SASP.
    J Biol Chem. 2025;301:108438.
    PubMed         Abstract available
    
    

    
    J Clin Invest

62. CHEN MK, Yamaguchi H, Gao Y, Xia W, et al
    FGFR3-induced Y158 PARP1 phosphorylation promotes PARP-inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models.
    J Clin Invest. 2025 May 29:e173757. doi: 10.1172/JCI173757.
    PubMed         Abstract available
    
    
63. THATTE J, Moises da Silva A, Borcsok J, Gudjonsson T, et al
    The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.
    J Clin Invest. 2025;135:e188165.
    PubMed         Abstract available
    
    

    
    J Nucl Med

64. MANSUR A, McConathy JE, Stringer-Reasor E, Rocque G, et al
    Quantitative [(89)Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI.
    J Nucl Med. 2025 Jun 5:jnumed.124.268931. doi: 10.2967/jnumed.124.268931.
    PubMed         Abstract available
    
    
65. RINNE SS, Vargas DB, Seo S, Veach D, et al
    (225)Ac alpha-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast Cancer.
    J Nucl Med. 2025 Jun 5:jnumed.125.269601. doi: 10.2967/jnumed.125.269601.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

66. GRAZIANO FD, Amakiri UO, Levy J, Shammas RL, et al
    Perioperative Venous Thromboembolism Chemoprophylaxis Does Not Increase Risk of Complications in Free Flap Breast Reconstruction.
    J Surg Oncol. 2025;131:1211-1221.
    PubMed         Abstract available
    
    
67. KIEFER J, Paidisetty P, Elmorsi RAI, Nguyen CHM, et al
    Contemporary Trends in Reconstruction for Patients With Sarcoma of the Breast.
    J Surg Oncol. 2025;131:1013-1023.
    PubMed         Abstract available
    
    
68. ZINDANI S, Khalil M, Rashid Z, Altaf A, et al
    Association of Socio-Environmental Burden and Inequality With Cancer Screening and Mortality.
    J Surg Oncol. 2025;131:1110-1117.
    PubMed         Abstract available
    
    
69. GRAZIANO FD, White DR, Plotsker EL, Shammas RL, et al
    Enhancing Patient Decision-Making in Breast Reconstruction: A Systematic Review of Decision Aid Efficacy.
    J Surg Oncol. 2025;131:1222-1235.
    PubMed         Abstract available
    
    
70. VASCONCELOS CS, Salgado MRT, Martins MR, Anunciacao CEC, et al
    Soluble sFas, sFasL, sPD1, and sPDL1 Analyses in the Peripheral Blood of Locally Advanced Breast Cancer Patients Before and After Neoadjuvant Chemotherapy.
    J Surg Oncol. 2025 Jun 2. doi: 10.1002/jso.27723.
    PubMed         Abstract available
    
    

    
    N Engl J Med

71. CARDOSO F, Parke S, Brennan DJ, Briggs P, et al
    Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2415566.
    PubMed         Abstract available
    
    
72. BIDARD FC, Mayer EL, Park YH, Janni W, et al
    First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
    N Engl J Med. 2025 Jun 1. doi: 10.1056/NEJMoa2502929.
    PubMed         Abstract available
    
    
73. JHAVERI KL, Im SA, Saura C, Loibl S, et al
    Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.
    N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2501796.
    PubMed         Abstract available
    
    
74. PARTRIDGE AH
    Menopausal Symptom Management in Breast Cancer Survivors - A Promising New Option.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMe2506475.
    PubMed        
    
    
75. CAMPONE M, De Laurentiis M, Jhaveri K, Hu X, et al
    Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
    N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2505725.
    PubMed         Abstract available
    
    
76. MAMOUNAS EP, Bandos H, White JR, Julian TB, et al
    Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
    N Engl J Med. 2025;392:2113-2124.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

77. BLYTH RRR, Laversin SA, Foxall RB, Savva C, et al
    Development and characterisation of a novel 3D in vitro model of obesity-associated breast cancer as a tool for drug testing.
    NPJ Breast Cancer. 2025;11:50.
    PubMed         Abstract available
    
    

    
    Oncology

78. DAWOOD S, Sandhir N, Akasheh M, El Khoury M, et al
    Genomic Landscape of Advanced Solid Tumors in Middle East and North Africa Using Circulating Tumor DNA in Routine Clinical Practice.
    Oncology. 2025;103:508-520.
    PubMed         Abstract available
    
    

    
    PLoS One

79. WELLER SC, Pappadis MR, Krishnan S, Stearnes MR, et al
    Understanding motivations of older women to continue or discontinue breast cancer screening.
    PLoS One. 2025;20:e0319141.
    PubMed         Abstract available
    
    
80. ISSA E, Lahoud R, Abi-Gerges A, Salameh P, et al
    Breast cancer screening practices during a multifaceted crisis: Data from Lebanon.
    PLoS One. 2025;20:e0325604.
    PubMed         Abstract available
    
    
81. HOU PH, Chang GR, Chao YT, Chang YT, et al
    Aripiprazole use and lowering the risk of breast cancer in patient with schizophrenia in a national cohort study.
    PLoS One. 2025;20:e0324257.
    PubMed        
    
    
82. LOGANATHAN T, Doss C GP
    Gut microbiota and its influence on the Gut-Brain axis in comparison with chemotherapy patients and cancer-free control data in Breast cancer-A computational perspective.
    PLoS One. 2025;20:e0324742.
    PubMed         Abstract available
    
    
83. WANG T, Zang B, Kong C, Li Y, et al
    Intelligent and precise auxiliary diagnosis of breast tumors using deep learning and radiomics.
    PLoS One. 2025;20:e0320732.
    PubMed         Abstract available
    
    
84. POPIC D, Marinovich ML, Houssami N, Hall J, et al
    How should artificial intelligence be used in breast screening? Women's reasoning about workflow options.
    PLoS One. 2025;20:e0323528.
    PubMed         Abstract available
    
    
85. MARGULIES BS, Likhitpanichkul M, Tripathy D
    Reshaping the landscape of locoregional treatments for breast cancer liver metastases: A novel, intratumoral, p21-targeted percutaneous therapy increases survival in BALB/c mice inoculated with 4T1 triple negative breast cancer cells in the liver.
    PLoS One. 2025;20:e0323621.
    PubMed         Abstract available
    
    
86. RIOKI JN, Mweu M, Rogena E, Songok EM, et al
    Factors associated with breast lesions among women attending select teaching and referral health facilities in Kenya: A cross-sectional study.
    PLoS One. 2025;20:e0309182.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

87. WEBER BW, Mao L, Salem K, Hitchcock M, et al
    Performance of Diagnostic Breast Imaging in Symptomatic Pregnant and Lactating Patients: Systematic Review and Meta-Analysis.
    Radiol Imaging Cancer. 2025;7:e240281.
    PubMed         Abstract available
    
    
88. DAVIS EA, Joe BN
    Rising Rates of Distant-Stage Breast Cancer: Trends Among U.S. Women.
    Radiol Imaging Cancer. 2025;7:e259012.
    PubMed        
    
    
89. MUNIR J, Nisha Y, Islam N, Bissell MB, et al
    Impact of Method of Detection of Breast Cancer on Clinical Outcomes in Individuals Aged 40 Years or Older.
    Radiol Imaging Cancer. 2025;7:e240046.
    PubMed         Abstract available
    
    

    
    Radiology

90. ESKREIS-WINKLER S, Bhowmik A, Kelly LH, Lo Gullo R, et al
    Adaptive Breast MRI Scanning Using AI.
    Radiology. 2025;315:e242924.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.